News
Feb, 2010
Fate Therapeutics Receives Allowance of First U.S. Patent for Induced Pluripotent Stem Cell Technology
Thursday 4 Feb, 2010
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Wednesday 3 Feb, 2010
Peakdale Molecular Limited Announces Innovative On-Site Research Collaboration With Pfizer Sandwich Laboratories
Monday 1 Feb, 2010
© 2008 Ochre Media. All rights reserved.